AL
ALIMP.PA Implanet SA
- Market cap
- EUR 19.2M
- P/E
- -
- P/B
- 59.81x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- 0.8/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is ALIMP.PA undervalued?
Graham numberThe Graham number of Implanet SA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Implanet SA fundamental analysis
2 of 11 checks passedROE 0/2
Negative ROE (-155.71%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.
ROA 0/2
The stock's ROA (-52.93%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.
PBV 2/2
With a remarkably low PBV ratio (0.28x), the stock offers substantial upside potential at a bargain price.
DER 0/2
The company has a high debt to equity ratio (192%), which means it owes a lot of money compared to what it actually owns, making it financially risky.
Revenue Growth 0/2
Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.
Net Profit Growth 0/2
This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.
Assets Growth 0/2
Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.
Graham Number 1/1
The Graham number of this company suggests that its stock price may be undervalued, indicating a potentially attractive investment opportunity.
Dividend Growth 0/2
The company's dividend growth has shown no improvement in the past three years, making it a less attractive investment option for those seeking increasing returns.
Dividend 0/2
The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.
Buffet Intrinsic Value 0/1
The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Implanet SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Implanet SA
Implanet S.A., together with its subsidiaries, manufactures and sells implants and medical instruments for orthopedic surgery in France, the United States, Europe, the Middle East, Africa, and internationally. The company offers spinal and knee products, including Jazz PF, Jazz Evo, Jazz Cap SP, Jazz Passer, Jazz Lock, Jazz Claw, Olea, Saxxo, Swingo, Shark, Origin, and Jazz Frame, as well as ISS-Jazz Screw systems for posterior fixation. It also provides an ultrasonic osteot…
Full company profileImplanet SA financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Implanet SA annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 7.83M | 7.84M | 6.72M | 7.41M | 3.89M | 6.14M | 8.03M | 7.45M | 9.41M | 12.5M | 28.5M |
| Gross Profit | 3.07M | 3.16M | 2.94M | 3.46M | 1.59M | 2.74M | 3.91M | 3.13M | 4.10M | 5.93M | 17.0M |
| Operating Income | -6.88M | -5.78M | -5.16M | -3.61M | -3.43M | -4.42M | -3.97M | -6.16M | -4.89M | -3.93M | -7.47M |
| EBITDA | -5.63M | -5.15M | -4.33M | -2.16M | -1.46M | -2.70M | -1.84M | -5.08M | -3.82M | -2.91M | -4.58M |
| Net Income | -7.29M | -6.61M | -5.55M | -3.65M | -3.98M | -4.61M | -3.54M | -6.68M | -4.37M | -4.38M | -8.56M |
| EPS | -16 | -11 | -7.43 | -3.07 | -1.27 | -0.54 | -0.17 | -0.17 | -0.04 | -0.03 | -0.06 |
| Balance Sheet | |||||||||||
| Total Assets | 16.5M | 12.6M | 8.85M | 9.65M | 8.70M | 16.7M | 14.5M | 10.6M | 14.9M | 18.4M | 17.7M |
| Total Liabilities | 6.80M | 6.28M | 6.45M | 8.21M | 7.68M | 13.9M | 10.9M | 10.8M | 14.2M | 18.0M | 19.5M |
| Shareholders' Equity | 9.66M | 6.29M | 2.40M | 1.44M | 1.02M | 2.80M | 3.54M | -174K | 727K | 404K | -1.72M |
| Cash & Short-term Investments | 6.07M | 3.61M | 400K | 450K | 1.14M | 1.87M | 531K | 248K | 1.60M | 3.01M | 1.01M |
| Total Debt | 3.70M | 2.25M | 2.64M | 4.12M | 4.66M | 9.61M | 6.80M | 6.15M | 6.50M | 5.92M | 5.46M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -5.89M | -4.47M | -4.44M | -2.81M | -3.07M | -3.52M | -2.40M | -1.45M | -2.32M | -589K | -1.80M |
| Capital Expenditure | 513K | 380K | 322K | 154K | 223K | 392K | 568K | 718K | 486K | 1.56M | 2.59M |
| Free Cash Flow | -6.41M | -4.85M | -4.77M | -2.96M | -3.29M | -3.91M | -3.04M | -2.17M | -2.81M | -2.15M | -4.39M |
| Ratios | |||||||||||
| ROE | -75.4% | -105.2% | -231.0% | -253.8% | -389.0% | -164.4% | -100.0% | - | -600.6% | -1,084.7% | - |
| ROA | -44.3% | -52.6% | -62.7% | -37.8% | -45.7% | -27.6% | -24.5% | -62.8% | -29.3% | -23.8% | -48.3% |
| Net Profit Margin | -93.1% | -84.3% | -82.6% | -49.2% | -102.2% | -75.1% | -44.1% | -89.6% | -46.4% | -35.1% | -30.0% |
| Debt to Equity | 0.38x | 0.36x | 1.10x | 2.87x | 4.56x | 3.43x | 1.92x | - | 8.94x | 14.66x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Implanet SA dividends
Implanet SA has not paid dividends in the last 9 fiscal years.
Last stock split: 1:40 on Feb 3, 2020.
Who owns Implanet SA
- Insiders 66.13%
- Institutions 0.00%
- Public & others 33.87%
- Shares outstanding 144M
- Free float 49.8M
Implanet SA company profile
- Company name
- Implanet SA
- Ticker
- ALIMP.PA
- ISIN
- FR0013470168
- Exchange
- Euronext Paris
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 49
- Fiscal year end
- December
- Address
- Technopole Bordeaux Montesquieu, Martillac, France, 33650
- Phone
- 33 5 57 99 55 55
- Website
- implanet.com
About Implanet SA
Implanet S.A., together with its subsidiaries, manufactures and sells implants and medical instruments for orthopedic surgery in France, the United States, Europe, the Middle East, Africa, and internationally. The company offers spinal and knee products, including Jazz PF, Jazz Evo, Jazz Cap SP, Jazz Passer, Jazz Lock, Jazz Claw, Olea, Saxxo, Swingo, Shark, Origin, and Jazz Frame, as well as ISS-Jazz Screw systems for posterior fixation. It also provides an ultrasonic osteotomy surgical system; and knee prostheses under the Madison name. The company exports its products. Implanet S.A. was founded in 2006 and is headquartered in Martillac, France.
Implanet SA management
4- Mr. Ludovic LastennetCEO, Commercial Director & Director
- Mr. David DieumegardVice President of Financial
- Ms. Yvanna PeigneOperations Manager
- Mr. Benjamin LetienneVP of Marketing & International Sales and Director